Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone 

References

• Argenziano M, Lombardi C, Ferrara B, et al. (2018). Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells. Oncotarget 9:35813–29.
   PubMedGoogle Scholar
• Autio KA, Dreicer R, Anderson J, et al. (2018). Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol 4:1344–51.
   PubMed Web of Science ®Google Scholar
• Cao C, Wang Q, Liu Y. (2019). Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Devel Ther 13:1087–98.
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–92.
   PubMed Web of Science ®Google Scholar
• Chang SS, O’Keefe DS, Bacich DJ, et al. (1999). Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–81.
   PubMed Web of Science ®Google Scholar
• Chen D, Jiang X, Liu J, et al. (2010). In vivo evaluation of novel pH-sensitive mPEG-Hz-Chol conjugate in liposomes: pharmacokinetics, tissue distribution, efficacy assessment. Artif Cells Blood Substit Immobil Biotechnol 38:136–42.
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang Y, Deng H, et al. (2020). Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines. Biomed Pharmacother 125:109988.
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng Y, Zhu C, Xiang C. (2020). Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomed Pharmacother 127:110181.
   PubMed Web of Science ®Google Scholar
• Chen Z, Penet MF, Nimmagadda S, et al. (2012). PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 6:7752–62.
   PubMed Web of Science ®Google Scholar
• Chou TC. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–6.
   PubMed Web of Science ®Google Scholar
• Cui T, Zhang S, Sun H. (2017). Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep 37:1253–60.
   PubMed Web of Science ®Google Scholar
• Ding Z, Wang D, Shi W, et al. (2020). In vivo targeting of liver cancer with tissue- and nuclei-specific mesoporous silica nanoparticle-based nanocarriers in mice. Int J Nanomed 15:8383–400.
   PubMed Web of Science ®Google Scholar
• Du C, Deng D, Shan L, et al. (2013). A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 34:3087–97.
   PubMed Web of Science ®Google Scholar
• Fan X, Zhao X, Qu X, Fang J. (2015). pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect. Int J Pharm 496:644–53.
   PubMed Web of Science ®Google Scholar
• Fu Q, Wang J, Liu H. (2020). Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles. Drug Deliv 27:1535–43.
   PubMed Web of Science ®Google Scholar
• Guo S, Zhang Y, Wu Z, et al. (2019). Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. Biomed Pharmacother 118:109225.
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217–27.
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, et al. (2019). Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother 112:108614.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. (2013). Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501–11.
   PubMed Web of Science ®Google Scholar
• Ketola K, Viitala M, Kohonen P, et al. (2016). High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. J Mol Biochem 5:12–22.
   PubMedGoogle Scholar
• Li C, Li H, Wang Q, et al. (2017). pH-sensitive polymeric micelles for targeted delivery to inflamed joints. J Control Release 246:133–41.
   PubMed Web of Science ®Google Scholar
• Li D, Cui R, Xu S, Liu Y. (2020). Synergism of cisplatin-oleanolic acid co-loaded hybrid nanoparticles on gastric carcinoma cells for enhanced apoptosis and reversed multidrug resistance. Drug Deliv 27:191–9.
   PubMed Web of Science ®Google Scholar
• Li K, Zhan W, Chen Y, et al. (2019). Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer. Front Pharmacol 10:1436.
   PubMed Web of Science ®Google Scholar
• Li N, Xie X, Hu Y, et al. (2019). Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am J Transl Res 11:1255–69.
   PubMed Web of Science ®Google Scholar
• Lin J, Wang X, Wu Q, et al. (2014). Development of salvianolic acid B-tanshinone II A-glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells. Int J Pharm 462:11–8.
   PubMed Web of Science ®Google Scholar
• Liu J, Cheng H, Han L, et al. (2018). Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 12:3199–209.
   PubMed Web of Science ®Google Scholar
• Lu X, Liu S, Han M, et al. (2019). Afatinib-loaded immunoliposomes functionalized with cetuximab: a novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Int J Pharm 560:126–35.
   PubMed Web of Science ®Google Scholar
• Men W, Zhu P, Dong S, et al. (2020). Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo. Drug Deliv 27:180–90.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, Ford OH, 3rd, et al. (2004). The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440–8.
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–41.
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, et al. (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–5.
   PubMed Web of Science ®Google Scholar
• SreeHarsha N, Maheshwari R, Al-Dhubiab BE, et al. (2019). Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy. Int J Nanomed 14:7419–29.
   PubMed Web of Science ®Google Scholar
• Suh MS, Shen J, Kuhn LT, Burgess DJ. (2017). Layer-by-layer nanoparticle platform for cancer active targeting. Int J Pharm 517:58–66.
   PubMedGoogle Scholar
• Sun N, Wang D, Yao G, et al. (2019). pH-dependent and cathepsin B activable CaCO3 nanoprobe for targeted in vivo tumor imaging. Int J Nanomed 14:4309–17.
   PubMed Web of Science ®Google Scholar
• Tambe P, Kumar P, Paknikar KM, Gajbhiye V. (2018). Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells. Int J Nanomed 13:7669–80.
   PubMed Web of Science ®Google Scholar
• Wang B, Hu W, Yan H, et al. (2021). Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. Biomed Pharmacother 136:111249.
   PubMed Web of Science ®Google Scholar
• Wang J. (2020). Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 14:823–32.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang SS, Heston WD, et al. (2014). Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther 13:2595–606.
   PubMed Web of Science ®Google Scholar
• Wang M, Zeng X, Li S, et al. (2019). A novel tanshinone analog exerts anti-cancer effects in prostate cancer by inducing cell apoptosis, arresting cell cycle at G2 phase and blocking metastatic ability. Int J Mol Sci 20:4459.
   PubMed Web of Science ®Google Scholar
• Xu C, Song RJ, Lu P, et al. (2018). pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy. Int J Nanomed 13:7229–49.
   PubMed Web of Science ®Google Scholar
• Yin N, Yu H, Zhang X, Lv X. (2020). Enhancement of pancreatic cancer therapy efficacy by type-1 matrix metalloproteinase-functionalized nanoparticles for the selective delivery of gemcitabine and erlotinib. Drug Des Devel Ther 14:4465–75.
   PubMed Web of Science ®Google Scholar
• Yugui F, Wang H, Sun D, Zhang X. (2019). Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles. Biomed Pharmacother 114:108820.
   PubMed Web of Science ®Google Scholar
• Zhang HW, Dang Q, Zhang ZW, Wu FS. (2017). Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer. J BUON 22:102–11.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu K, Zeng H, et al. (2019). Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity. Int J Nanomed 14:6061–71.
   PubMed Web of Science ®Google Scholar
• Zhang R, Ru Y, Gao Y, et al. (2017). Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther 11:2631–42.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang P, Zhu T. (2019). Ovarian carcinoma biological nanotherapy: comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. Biomed Pharmacother 109:475–83.
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen Q, Liu W, et al. (2014). Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomed 10:257–70.
   PubMed Web of Science ®Google Scholar